SLDB (Solid Biosciences) E10: $-21.66 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $9.07
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences E10?

Solid Biosciences SLDB +2.26% 34 E10 is $-21.66 as of Jun. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Solid Biosciences's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.380. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-21.66 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-13), Solid Biosciences's current stock price is $9.065. Solid Biosciences's E10 for the quarter that ended in Jun. 2026 was $-21.66. Solid Biosciences's Shiller PE Ratio of today is .


Solid Biosciences  (NAS:SLDB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Solid Biosciences E10 Related Terms


Solid Biosciences E10 Historical Data

* Premium members only.

The historical data trend for Solid Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solid Biosciences E10 Chart

Solid Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Solid Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -21.66

SLDB vs MNPR, DSGN, CLYM: E10 Comparison

For the Biotechnology subindustry, Solid Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solid Biosciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Shiller PE Ratio falls into.


SLDB
34GF Score
Solid Biosciences Inc SLDB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solid Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Solid Biosciences's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.38/333.9520*333.9520
=-0.380

Current CPI (Jun. 2026) = 333.9520.

Solid Biosciences Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201612 -3.623 241.432 -5.011
201703 -0.011 243.801 -0.015
201706 -8.821 244.955 -12.026
201709 -10.533 246.819 -14.251
201712 -6.743 246.524 -9.134
201803 -8.100 249.554 -10.839
201806 -7.800 251.989 -10.337
201809 -8.250 252.439 -10.914
201812 -9.600 251.233 -12.761
201903 -12.750 254.202 -16.750
201906 -11.400 256.143 -14.863
201909 -10.050 256.759 -13.071
201912 -9.750 256.974 -12.671
202003 -8.400 258.115 -10.868
202006 -5.850 257.797 -7.578
202009 -6.600 260.280 -8.468
202012 -4.650 260.474 -5.962
202103 -2.850 264.877 -3.593
202106 -2.550 271.696 -3.134
202109 -2.401 274.310 -2.923
202112 -2.456 278.802 -2.942
202203 -3.370 287.504 -3.914
202206 -3.330 296.311 -3.753
202209 -2.710 296.808 -3.049
202212 -0.680 296.797 -0.765
202303 -1.540 301.836 -1.704
202306 -1.250 305.109 -1.368
202309 -1.050 307.789 -1.139
202312 -1.000 306.746 -1.089
202403 -0.640 312.332 -0.684
202406 -0.610 314.175 -0.648
202409 -0.790 315.301 -0.837
202412 -1.020 315.605 -1.079
202503 -0.590 319.799 -0.616
202506 -0.420 322.561 -0.435
202509 -0.480 324.800 -0.494
202512 -0.530 324.054 -0.546
202603 -0.520 330.213 -0.526
202606 -0.380 333.952 -0.380

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-21.66 mean?
Solid Biosciences (SLDB) has a E10 of $-21.66 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Solid Biosciences and its competitors.
Is Solid Biosciences' E10 too high?
Solid Biosciences' current E10 is $-21.66. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' E10 compare to MNPR and DSGN?
Solid Biosciences' E10 of $-21.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Solid Biosciences and its competitors. Solid Biosciences's current E10 is $-21.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current E10 of $-21.66. The current E10 is $-21.66. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current E10 is $-21.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.07
Price